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Depression is a complex and heterogeneous disorder affecting millions of Americans.
There are several different medications and other treatments that are available and
effective for many patients with depression. However, a substantial percentage of patients
fail to achieve remission with these currently available interventions, and relapse rates
are high. Therefore, it is necessary to determine both the mechanisms underlying the
antidepressant response and the differences between responders and non-responders
to treatment. Delineation of these mechanisms largely relies on experiments that utilize
animal models. Therefore, this review provides an overview of the various mouse models
that are currently used to assess the antidepressant response, such as chronic mild
stress, social defeat, and chronic corticosterone. We discuss how these mouse models
can be used to advance our understanding of the differences between responders and
non-responders to antidepressant treatment. We also provide an overview of experimental
treatment modalities that are used for treatment-resistant depression, such as deep
brain stimulation and ketamine administration. We will then review the various genetic
polymorphisms and transgenic mice that display resistance to antidepressant treatment.
Finally, we synthesize the published data to describe a potential neural circuit underlying
the antidepressant response and treatment resistance.
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INTRODUCTION
Understanding the neurobiological basis of a highly complex
disease like depression remains one of the foremost challenges
for modern psychiatry. In patients, the essential feature of a
major depressive episode is a period of at least 2 weeks dur-
ing which there is either depressed mood or the loss of inter-
est or pleasure in nearly all activities (American Psychiatric
Association, 2013). These episodes are recurrent in the major-
ity of cases. The twelve-month prevalence of major depressive
disorder is approximately 7% in the US and approximately 32–
35 million adults in the US population (16%) experience an
episode of major depression in their lifetime (Kessler et al., 2003).
Depression is ultimately associated with shorter life spans and
greater risk of heart disease (Kessler, 2009). However, symptoms
are diverse and vary from patient to patient. In addition to psy-
chotherapy, several approved classes of drugs with antidepressant
activity have been developed, including selective serotonin reup-
take inhibitors (SSRIs), tricyclic antidepressants (TCAs), nore-
pinephrine reuptake inhibitors (NRIs), and monoamine oxidase
inhibitors (MAOIs) (Samuels et al., 2011). Furthermore, various
other interventions have demonstrated efficacy for depression,
including electroconvulsive therapy (ECT), vagus nerve stim-
ulation (VNS), and transcranial magnetic stimulation (TMS)
(Holtzheimer and Mayberg, 2011a).
Unfortunately there are two major problems with these inter-
ventions. First, for the antidepressants, there is a significant delay
between the start of treatment and any beneficial effects (Samuels
et al., 2011). SSRIs, which are the most commonly prescribed
class of antidepressant, do not show beneficial effects until 2
weeks after the start of treatment and these effects are not max-
imal until 6–9 weeks after the start of treatment (Artigas et al.,
1996; Gardier et al., 1996). Thus, one major goal of current
research is to develop faster acting antidepressants. Although
this work is in its infancy, potential faster acting antidepressants
include Serotonin Receptor 4 (5-HT4) agonists and ketamine
(Berman et al., 2000; Lucas et al., 2007; Mendez-David et al.,
2013a). The second major issue with current interventions is
treatment-resistance. Response rates for commonly used antide-
pressants are low, and remittance rates are even lower. There are
many potential reasons for these low rates, including the fact that
diverse sets of symptoms can all result in a depression diagno-
sis and, as discussed later, the genetics underlying depression are
extremely complex. The largest study on response and remittance
to antidepressants was a 7-year program known as sequenced
treatment alternatives to relieve depression (STAR∗D). In the
STAR∗D study, unipolar depression patients were enrolled in a
multistep treatment program. All steps lasted for 12 weeks or until
the patient could not tolerate the treatment. The first step for all
patients was treatment with citalopram, a common SSRI. Only
28% of patients demonstrated remission with citalopram treat-
ment as determined by the Hamilton Rating Scale of Depression
(HRSD17), and only 33% demonstrated remission as determined
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by the Quick Inventory of Depressive Symptomatology-Self-
Report (QIDS-SR16) scale (Rush et al., 2006a; Warden et al.,
2007). These response rates to citalopramwere similar to previous
studies (Trivedi et al., 2006a,b; Warden et al., 2007). If the patients
did not remit and wanted to continue in the study, they were then
randomly assigned a treatment course in step 2. These treatment
courses included either adjunctive therapies with either the atyp-
ical antidepressant bupropion, the Serotonin 1A receptor partial
agonist buspirone, or cognitive therapy, or medication switches to
bupropion, the SSRI sertraline, the NRI venlafaxine, or cognitive
therapy. Only about 25% of participants entering step 2 remitted
according to QIDS-SR16 (Rush et al., 2006b; Trivedi et al., 2006a;
Warden et al., 2007). The different treatment courses all resulted
in similar remittance profiles. Remittance rates were even lower
for steps 3 (patients were either switched to the second generation
TCA nortriptyline or the noradrenergic and specific serotoner-
gic antidepressant (NaSSA) mirtazapine or were augmented with
lithium, nortriptyline, sertraline, or venlafaxine) and 4 (patients
were switched to theMAOI tranylcypromine ormirtazapine com-
bined with venlafaxine). Similar to step 2, the different treatment
courses all resulted in similar remittance profiles for steps 3 and 4.
In addition, the patients that took more steps to remit or respond
displayed more relapses in a long-term follow-up study (Rush
et al., 2006a). Overall, approximately 20% of patients remain
symptomatic despite multiple, and often aggressive, interven-
tions (Rush et al., 2006a; Holtzheimer and Mayberg, 2011a,b).
Thus, another major goal of current research is to find targets for
better antidepressant treatments that will achieve and maintain
remission.
Patients that do not show any response to any of the steps
of treatment suffer from treatment-resistant depression (TRD).
TRD is generally defined as depression that does not respond to
two or more antidepressants from different classes given adequate
time, dose, and compliance. However, these classes of antide-
pressants are usually limited to drugs that target monoaminergic
neurotransmitters. More effective medications or adjunctive ther-
apies will rely on basic research to identify targets that are distinct
from monoaminergic signaling. To begin to understand TRD at a
basic research level, first it is essential to develop animal models
with relevant phenotypic features to reveal treatment responsive-
ness (Samuels et al., 2011). Importantly, it is very difficult to
use rodent models to study resistance to multiple different treat-
ments. However, rodent models are advantageous to study non-
responsiveness to an initial line of treatment because molecular
parameters such as protein and gene expression can be directly
compared across multiple brain regions between responders and
non-responders.
ANIMAL MODELS OF DEPRESSION AND TREATMENT
RESISTANCE
No genetic variants with high penetrance that cause depression
are known (Lohoff, 2010; Samuels et al., 2011). Thus, several
animal models of depression were developed based on whether
the animals showed a response to antidepressants. While this
approach has its uses, it is incompatible with attempts to study
TRD. In the last decade there has been a move toward using ani-
mal models that rely on different means of chronically exposing
rodents to stressful experiences. These manipulations induce
states that present depression- and anxiety-like characteristics in
a wide variety of behavioral tests. Subsequently, the animals can
then be treated with antidepressants to test for responsiveness.
Thus, these models achieve considerable face and construct valid-
ity and do not suffer from a flawed approach of being based solely
on responsiveness to antidepressants. Importantly, these manip-
ulations result in models of both anxiety and depression. While
anxiety and depression are generally conceived of as distinct
psychiatric disorders, they have a high comorbidity with co-
occurrence rates up to 60% in patients (Gorman, 1996; Leonardo
and Hen, 2006). Ultimately, given that depression is a highly het-
erogenous disease, no one animal model will accurately replicate
the various combinations of phenotypes that are seen in depres-
sion. Successful studies will analyze data and utilize the beneficial
aspects from several different animal models.
CHRONIC MILD STRESS
Chronic mild stress (CMS) was initially developed in rats using
multiple stressors as a behavioral model of anhedonia that could
be reversed by treatment with a TCA (Katz, 1982). Further
work demonstrated that variations using more mild stressors
also yielded depression- and anxiety-like characteristics, that mice
were also susceptible to chronic stress, and that the induced
depression- and anxiety-like characteristics could be reversed
by chronic treatment with multiple classes of antidepressants
(Willner et al., 1987; Willner, 2005; Surget et al., 2008).
There are a few variations of CMS. The classic CMS involves a
protocol where animals are subjected to different types of mild
stressors for several weeks (Willner et al., 1987; Willner, 2005;
Hill et al., 2012). Some of these stressors include cage tilting,
frequent bedding changes, light-dark cycle changes, and/or the
presence of predator scents. These stressors are typically given in a
repeated pattern for several hours per day. However, classic CMS
is no longer widely used because of difficulties replicating results
across laboratories (Nestler et al., 2002). Modified protocols,
including chronic unpredictable stress (CUS) and unpredictable
chronic mild stress (UCMS) are more useful. In both CUS and
UCMS, several stressors are presented and the pattern is changed
so that animals are unable to predict the next stressor. This
unpredictability increases the amount of stress that the animals
experience. CUS and UCMS appear to have ecological valid-
ity as they mimic stressful life experiences that may precipitate
depression in humans (Mineur et al., 2006; Hill et al., 2012).
Importantly, different mouse strains have different levels
of sensitivity to the UCMS procedure. Some strains do not
develop a depressive phenotype at all while others display robust
depression-like behavior (see Supplementary Table 1 for an
overview). Overall, BALB/c mice are the most sensitive to UCMS,
while C57BL/6 mice are only slightly susceptible (Ibarguen-
Vargas et al., 2008; Yalcin et al., 2008; Schweizer et al., 2009).
However, even within strains there are differences in susceptibility
over various behavioral and cellular readouts. Thus, care must be
taken when choosing a strain for UCMS experiments.
Importantly, UCMS animal models can be used to model and
assess treatment resistance. Wiborg and colleagues found that a
UCMS variant significantly decreased sucrose consumption and
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neurogenesis in rats (Jayatissa et al., 2006). Chronic treatment
with escitalopram (a SSRI) resulted in a bimodal distribution
in which one group showed increased sucrose consumption
while the other did not. There was a correlation between
the animals that showed increased sucrose consumption and
reversal of the neurogenesis deficit. A follow-up study used
a proteomic approach to compare the ventral hippocampus
between responders and non-responders to antidepressant treat-
ment (Bisgaard et al., 2007). The authors found that DRP-2
(dihydropyrimidinase-related protein 2) is a potential biomarker
for escitalopram resistance. In a different study, Isingrini and
colleagues recently used UCMS to model resistance in mice to
fluoxetine (a SSRI) (Isingrini et al., 2010). The authors divided
mice into several groups: fluoxetine/regular diet, fluoxetine/high
fat diet, saline/regular diet, and saline/high fat diet. Each of these
groups was then subjected to either control or multiple UCMS
protocols. Depression-like behaviors were tested before and after
each of the UCMS periods by assessing coat state, splash test
results, and behavior in a reward maze test. The UCMS proce-
dures resulted in depression-like behaviors in both the regular and
high fat diet groups. However, fluoxetine treatment only reversed
the effects of UCMS in the regular diet group. This suggests that
diet correlates with response to antidepressant treatment. Taken
together, these studies strongly suggest that UCMS is a reason-
able animal model for studying non-responders to antidepressant
treatment.
SOCIAL DEFEAT
Social defeat is an emerging animal model of depression. While
schedules may differ by experiment, the basic principles are the
same. An experimental animal is placed in the home cage of a
bigger and more aggressive strain for several minutes at a time.
This is usually done repeatedly over a course of several days with
different aggressors each time, resulting in multiple experiences
of defeat from the more aggressive strain. At the end of the pro-
cedure, the experimental animal is tested for social interaction by
being placed in a home cage of the aggressive strain, but with-
out the threat of being attacked or defeated. Interestingly, in this
model, some of the animals appear resilient to the depressive phe-
notype while others exhibit susceptibility (Krishnan et al., 2007).
In addition, the phenotypes induced by social defeat in suscepti-
ble mice can be reversed with antidepressant treatment (Tsankova
et al., 2006).
While treatment-resistance has not specifically been assessed
in animals that are susceptible to social defeat, there are paral-
lels between responders and non-responders to antidepressant
treatment and animals that are resilient and susceptible to social
defeat, respectively. It is even possible that molecular studies into
the differences between resilience and susceptibility may pro-
vide biomarkers that can help to predict antidepressant response.
Therefore, a review of the studies into resilience and susceptibility
is provided below.
Several studies have found that there are specific gene reg-
ulation and methylation differences between mice that are sus-
ceptible and resilient to social defeat. The majority of these
studies come from Nestler and colleagues and focus on differ-
ences in the nucleus accumbens (NAc), a brain region in which
manipulations can exert dramatic effects on depression-related
behaviors (Willner, 1983; Zacharko and Anisman, 1991; Willner
et al., 1992; Nestler and Carlezon, 2006). There is a genome-
wide increase in dimethylK9/K27-H3 in gene-promoter regions
immediately upstream of transcription start sites in animals that
displayed the susceptible phenotype (Wilkinson et al., 2009).
Social defeat also increases phospho-CREB close to transcription
start sites and decreases phospho-CREB that is distant from start
sties in susceptible animals. Interestingly, chronic treatment with
imipramine (a TCA) reverses the H3-methylation and phospho-
CREB changes in susceptible animals. Resilient mice show similar
H3-methylation and phospho-CREB binding as control animals.
In a follow-up study, Nestler and colleagues found downregula-
tion of dishevelled-2 (DVL) protein in the NAc of susceptible,
but not resilient, mice (Wilkinson et al., 2011). Blockade of
DVL increases susceptibility to social defeat. Interestingly, the
mechanisms underlying resilience to social defeat have also been
investigated. Induction of the transcription factor FosB in the
NAc is necessary and sufficient for resilience (Vialou et al., 2010).
Interestingly, fluoxetine-mediated induction ofFosB in the NAc
is also necessary for reversal of the behavioral effects of social
defeat in susceptible mice (Vialou et al., 2010). Taken together,
these studies begin to address the molecular mechanisms under-
lying susceptibility to social defeat. In addition, the FosB
study suggests that there are direct parallels between mechanisms
underlying resilience and the response to antidepressants.
In addition to these molecular studies, there are also other
studies that have assessed differences in the neural circuitry
between mice that are resilient and susceptible to social defeat.
In vivo recordings found that high levels of activity in the ventral
tegmental area (VTA), a midbrain region containing dopaminer-
gic neurons that project to the NAc and other areas, are associated
with increased susceptibility to social defeat (Cao et al., 2010).
Interestingly, chronic fluoxetine treatment decreases firing and
bursting rates of dopaminergic neurons in the VTA of susceptible
mice but not control mice. A follow-up optogenetic study fur-
ther clarified that induction of phasic, but not tonic, firing in the
VTA induces a susceptible phenotype to social defeat (Chaudhury
et al., 2013). Furthermore, specific optogenetic inhibition of the
VTA-NAc projection induces resilience, while inhibition of the
VTA-medial prefrontal cortex (mPFC) projection induces suscep-
tibility. Taken together, these studies suggest that susceptibility
and resilience to social defeat are encoded by a circuit containing
VTA projections to the NAc and mPFC, and provide a framework
for identifying the neural circuitry underlying the brain’s response
to stress. It will be interesting to further assess if this same
circuitry is involved in mediating response to antidepressants.
CHRONIC CORTICOSTERONE
Several labs have mimicked the effects of chronic stress in ani-
mals through administration of glucocorticoids (Ardayfio and
Kim, 2006; Gourley et al., 2008a,b,c; Murray et al., 2008; David
et al., 2009). Glucocorticoid hormones are secreted by the adrenal
gland in response to stress (McEwen, 1999). Therefore, chronic
administration of chronic corticosterone (CORT), a glucocorti-
coid, can model depression in animals. CORT is a stress hormone
that is analogous to cortisol in humans, and serum levels of
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CORT are increased in stressed and depressed animals. CORT is
administered either by daily intraperitoneal (IP) injections or by
placement in the homecage drinking water of the animals.
Several studies have found that CORT administration results
in depression- and anxiety-related behavior. Both acute and
chronic CORT injections result in increased immobility in tests
that are often associated with depression-related behavior, such as
forced swim and tail suspension (Murray et al., 2008; Zhao et al.,
2008). Chronic, but not acute, CORT treatment affects behav-
ior in anxiety-related tasks. More specifically, chronic CORT
increases emergence in the light-dark test and latency to feed in
the novelty suppressed feeding (NSF) test, and decreases sucrose
consumption (Ardayfio and Kim, 2006; Gourley et al., 2008c;
David et al., 2009). Chronic corticosterone (35μg/ml in the
drinking water) also decreases several measures of adult hip-
pocampal neurogenesis, a process that is necessary for the antide-
pressant response (Santarelli et al., 2003; Murray et al., 2008;
David et al., 2009). In addition, chronic treatment with multiple
classes of antidepressants, including SSRIs, TCAs, norepinephrine
reuptake inhibitors (NRIs), and melatonergics, can reverse the
behavioral and neurogenic effects of chronic corticosterone in
most, but not all, animals (David et al., 2009; Samuels et al., 2011;
Rainer et al., 2012). Taken together, these studies demonstrate
that chronic corticosterone treatment provides a useful model for
modeling depression in rodents with face and construct validity.
One study used the chronic corticosterone model to study
a potential biomarker for predicting antidepressant treatment
response. David and colleagues found that β–arrestin 1 levels
in peripheral blood mononuclear cells (PBMCs) were decreased
in mice exposed to chronic corticosterone. Interestingly, chronic
treatment with fluoxetine reversed this decrease in β–arrestin 1
levels. Therefore, the chronic corticosterone paradigm may prove
useful for screening potential biomarkers for treatment response
(Mendez-David et al., 2013b).
Only one study has attempted to model TRD using
corticosterone-treated mice (Samuels et al., 2014). As alluded to
above, there is usually a subgroup of animals pretreated with
corticosterone that do not show a response to subsequent antide-
pressant treatment. This subgroup is most apparent in the NSF
test, which shows a bimodal distribution potentially indicative
of responders and non-responders to antidepressant treatment
(Samuels et al., 2011). This same subgroup of animals that has
a higher latency in the NSF also shows less of a response to
antidepressant treatment in the forced swim test. Therefore, this
subgroup of animals, which shows a differential response across
multiple behavior tests, can be used as a model of non-response
to antidepressant treatment (Samuels et al., 2011, 2014). We
used a microarray approach to assess differences in the dentate
gyrus of these mouse models of responders and non-responders.
Interestingly, when comparing the dentate gyrus of responders
and non-responders, we found an overall shift in genomic tone
(Samuels et al., 2014). Pathway analysis of the probe sets from
this study suggest that several signaling pathways, such as TGFβ
and NFκB, contain multiple genes that show significant dif-
ferences in expression between responders and non-responders
(Samuels et al., 2014). Further work into identifying the molec-
ular mechanisms underlying the differences between responders
and non-responders to antidepressant treatment should provide
additional insight into TRD.
THERAPEUTIC AVENUES FOR TREATMENT-RESISTANT
DEPRESSION
As mentioned above, only 36.8% of participants in the first step
of the STAR*D study (and only a total of 67% after several steps)
achieved remission of symptoms (Rush et al., 2006a). While ani-
mal models are starting to make progress into identifying the
molecular mechanisms and neural circuitry underlying TRD,
new therapeutic avenues are required immediately. In addition
to antidepressant drugs, several other treatments are currently
used in the clinic. These include electroconvulsive therapy (ECT),
transcranial magnetic stimulation (TMS), and vagal nerve stim-
ulation (VNS) (Avery et al., 2006; Merkl et al., 2009; Bajbouj
et al., 2010; Holtzheimer and Mayberg, 2011a). In recent stud-
ies, TMS elicited a 30.6% response rate and VNS elicited a 53.1%
response rate and 38.9% remission rate in TRD patients (Avery
et al., 2006; Bajbouj et al., 2010). Therefore, while these methods
are effective for some patients, the majority of TRD patients are
in need of more effective treatments. There are two procedures
that are currently experimental, deep brain stimulation (DBS)
and ketamine administration, that show promise as potentially
better treatments for TRD.
DEEP BRAIN STIMULATION
DBS involves implantation of electrodes into brain regions and
subsequent stimulation. It is somewhat similar to a pacemaker
in that it delivers chronic electrical pulses to regulate firing. This
method was originally developed to treat Parkinson’s disease, but
has been expanded to other disorders such as obsessive com-
pulsive and major depression (Mayberg et al., 2005; Perlmutter
and Mink, 2006; Holtzheimer and Mayberg, 2011a). Stimulation
parameters vary widely, but generally the settings are between 60–
130Hz for the frequency, 60–200μs for the pulse width, and 2–10
volts for the amplitude (Holtzheimer and Mayberg, 2011a).
Several different brain regions have been targeted by DBS to
treat TRD. In a seminal study, Mayberg and colleagues found sig-
nificant antidepressant effects in four of six TRD patients when
they targeted white matter tracts adjacent to the subgenual cingu-
late (SGC) (Brodmann area 25). The TRD patients in this study
met stringent criteria for treatment resistance that was defined
as failure to respond to a minimum of four different antide-
pressant treatments, including medications, and evidence-based
psychotherapy or electroconvulsive therapy. A short-term follow-
up study of 20 patients found a 60% response rate after sixmonths
of chronic DBS (Lozano et al., 2008), and a more long-term
follow-up study found a 60% response rate and 50% remission
after 3 years of chronic stimulation (Kennedy et al., 2011). DBS
of the ventral capsule/ventral striatum (VC/VS) also produces
significant antidepressant effects. A recent study found a 40%
response rate after six months and a 53% response rate at the
last follow-up (24 ± 15 months) in 15 TRD patients (Malone
et al., 2009). NAc, which as mentioned above regulates resilience
and susceptibility to social defeat, can also be targeted by DBS.
An initial report found improvements in depression ratings and
hedonic responses in three TRD patients that received DBS of
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NAc (Schlaepfer et al., 2008). Interestingly, these improvements
were reversed when the NAc stimulation was turned off. A follow-
up study of 10 patients found a 50% response rate after 12months
of chronic DBS of NAc (Bewernick et al., 2010). In addition
to these brain regions, single case reports found antidepressant
effects in TRD patients with DBS of either the inferior thala-
mic peduncle or the habenula (Jimenez et al., 2005; Sartorius
and Henn, 2007). Taken together, these studies suggest that DBS
can elicit antidepressant responses in approximately 50% of TRD
patients.
While DBS is already being used in clinical experiments, ani-
mal models may still be able to help further advance this proce-
dure. For example, if TRD is modeled in animals with chronic
stress-related protocols, then techniques such as optogenetics can
be used to further parse out potential sites for DBS in humans.
KETAMINE
Recent studies have found that ketamine, a NMDA receptor
antagonist, elicits rapid and extended antidepressant effects.
Initial studies performed in rodents found that NMDA receptor
antagonists have antidepressant effects in the forced swim and
tail suspension tests, in learned helplessness paradigms, and in
animals exposed to chronic stress (Trullas and Skolnick, 1990;
Meloni et al., 1993; Moryl et al., 1993; Papp and Moryl, 1994;
Layer et al., 1995; Przegalinski et al., 1997). An initial study into
the effectiveness of ketamine in four human depression patients
resulted in a rapid (within 72 h) antidepressant effect relative to
control infused patients (Berman et al., 2000). Thus, ketamine
may be a potentially useful treatment for TRD patients.
Zarate and colleagues were the first to assess the usefulness of
ketamine administration to TRD patients (Zarate et al., 2006).
The subjects that received ketamine infusions (0.5mg/kg) showed
significant improvements in depression measures within 110min
of administration. The authors found a 71% response rate and
29% remission rate on the day after ketamine infusion. 35% of
the patients maintained the response for at least 1 week. Given
that the effects of a single dose of ketamine are transient, a follow-
up study assessed the efficacy of repeated ketamine doses for
TRD patients (Aan Het Rot et al., 2010). Nine out of ten par-
ticipants reported a response in symptoms on the day after the
initial ketamine infusion and after the sixth and final infusion.
Importantly, the authors found that ketamine treatment must
be maintained as eight of the nine patients that responded to
ketamine relapsed 19 days on average after the final infusion (Aan
Het Rot et al., 2010). Taken together, these studies show that
ketamine administration is a feasible and effective treatment for
patients suffering from TRD.
Based on these studies and others, ketamine seems to be
equally efficacious for all depression patients, whether they had
received prior medications or not. Importantly, ketamine works
through a distinct mechanism (antagonism of NMDA receptors)
to elicit effects than traditional antidepressants, which generally
target monoaminergic neurotransmitter systems. Therefore, the
effectiveness of ketamine underscores the importance of discov-
ering distinct mechanisms for treatment of TRD. As mentioned
above, TRD is generally defined as depression that does not
respond to two or more antidepressants from different classes.
However, since these classes of antidepressants are usually limited
to traditional antidepressants that target monoaminergic neuro-
transmitters, drugs that target distinct mechanisms will likely be
the most beneficial for TRD patients.
While ketamine looks very promising in clinical experiments,
there are still obstacles to it becoming widely used for treatment of
depression in clinics. Perhaps the most significant obstacle is that
ketamine is an abused recreational drug that induces a dissocia-
tive anesthesia-like state (Bergman, 1999). Ketamine is a schedule
III controlled substance in the United States and a schedule I
narcotic in Canada. Some of the patients in the experimental
trials exhibited adverse effects including perceptual disturbances
and transient dissociative symptoms (Zarate et al., 2006; Aan
Het Rot et al., 2010). Therefore, it is incumbent upon basic
research to determine the mechanism by which ketamine elicits
antidepressant actions so that safer drugs can be developed.
Since the discovery that ketamine is a fast acting antidepres-
sant in depression patients, there have been several preclinical
studies assessing its effects in rodents. An initial study found
that ketamine shows rapid antidepressant-like properties in mice
exposed to a learned helplessness paradigm and the forced swim
test (Maeng et al., 2008). In addition, ketamine rapidly amelio-
rates anhedonic and anxiogenic behaviors induced by CUS in rats
(Li et al., 2011). A few studies have attempted to use rodent mod-
els to assess the mechanisms underlying the antidepressant effects
of ketamine. Monteggia and colleagues found that the antidepres-
sant effects of ketamine in mice depend on eukaryotic elongation
factor (eEF2) kinase-mediated rapid synthesis of brain-derived
neurotrophic factor (BDNF) (Autry et al., 2011). Interestingly,
eEF2 kinase inhibitors also produced rapid antidepressant-like
effects in the forced swim test. In another study, Duman and col-
leagues reported that ketamine rapidly activates the mammalian
target of rapamycin (mTOR) pathway, which in turn resulted in
increased synaptogenesis in the prefrontal cortex (Li et al., 2010).
Importantly, the effects of ketamine on synaptogenesis and behav-
ior are blocked by pretreatment with rapamycin. Taken together,
these studies demonstrate that ketamine also shows rapid antide-
pressant effects in rodents, and that eEF2 kinase and mTOR
are potential targets for novel therapeutic interventions. Further
preclinical studies into the mechanisms underlying the antide-
pressant effects of ketamine should lead to additional targets for
new antidepressants that are fast acting and elicit high response
rates (Krystal et al., 2013).
One hypothesis stemming from these ketamine studies and
other studies is the magnesium depletion model of depression.
NMDA receptors are ionotropic glutamate receptors, and at rest
the ion channels are blocked by magnesium. Voltage-dependent
activation is required to remove the magnesium block and permit
ion flow through the NMDA receptor channel. The magnesium
depletion model proposes that decreased magnesium levels result
in NMDA receptor overactivity and, as a consequence, depres-
sion and anxiety-like symptoms (Zarate et al., 2013). In this
model, ketamine may elicit antidepressant effects by reversing the
NMDA receptor overactivity. Interestingly, a compound known as
Magtein increases magnesium levels in the brain, increases synap-
togenesis in the PFC, and elicits antidepressant-like effects in the
forced swim test and learned helplessness paradigm (Zarate et al.,
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2013). Thus, drugs that increase magnesium availability in the
brain may also result in rapid antidepressant effects with high
response rates.
MECHANISMS UNDERLYING DEPRESSION AND
TREATMENT RESISTANCE
Much of what is known about the molecular mechanisms under-
lying depression and antidepressant treatment come from pub-
lications describing genetically mutated mice that were assessed
in anxety- and depression-related behavioral tasks. There are
several publications that can be sorted into categories based
on the nature of the genetic manipulation. These categories
include neurotrophic factors, the serotonergic system, the glu-
tamatergic system, the dopaminergic system, the hypothalamic–
pituitary–adrenal (HPA) axis, themonoamine oxidase system, the
noradrenergic system, and other systems (Kreiner et al., 2013)
(Supplementary Table 2). These studies have deciphered many
of the mechanisms by which known antidepressants elicit their
effects. Therefore, an involved discussion of all of these genetic
mutants is somewhat less important in the context of under-
standing TRD. However, these studies can provide information
about the various brain regions that should be targeted in order to
have an antidepressant response and thus may be able to inform
an unbiased circuit-based approach to understanding TRD. An
overview of several of these published genetic mutants is therefore
provided in Supplementary Table 2.
There are a few genetic mutant models that are worth dis-
cussing in more depth. These genetic models are not based on
responsiveness to known antidepressants but are instead based on
polymorphisms found in the human population. These include
polymorphisms in the genes encoding the neurotrophic factor
BDNF, the serotonin transporter (5-HTT/SERT) and the sero-
tonin 1A (5-HT1A) receptor.
Val66Met POLYMORPHISM IN BDNF
There are many studies assessing the role of BDNF in
depression-related behavior and the antidepressant response (see
Supplementary Table 2 for an overview). BDNF has been such
an intense focus of interest because there is a single nucleotide
polymorphism (SNP) found in the human gene encoding BDNF.
This SNP results in a Met substitution for Val at codon 66
(Val66Met) in the prodomain of the gene encoding BDNF. This
SNP is common in humans, with an allele frequency of 20–30%
in the Caucasian population (Shimizu et al., 2004). Humans that
are homozygous for the Met allele have smaller hippocampal
volumes and perform poorly in hippocampus-dependent mem-
ory tasks (Egan et al., 2003; Hariri et al., 2003; Szeszko et al.,
2005; Bueller et al., 2006). In order to better understand the role
of this SNP in depression, Francis Lee and colleagues modeled
Val66Met in mice (Chen et al., 2006). Interestingly, similar to
humans, mice that were homozygous for the Met allele showed
an altered hippocampal anatomy. The homozygous Met allele
mice also exhibited defective BDNF secretion from neurons and
increased anxiety in a stressful environment. In addition, mice
that were homozygous for the Met allele responded to treatment
with desipramine but were resistant to treatment with fluoxetine
(Chen et al., 2006). While subsequent studies in humans have
provided less consistent results, a recent meta-analysis revealed a
better response to fluoxetine treatment among depressed patients
carrying the Val66Met heterozygous allele than patients with
homozygous allele (Zou et al., 2010a,b). By contrast, it was
also reported that the Val66Met mutation resulted in resistance
to antidepressant treatment (Kocabas et al., 2011). Thus, resis-
tance to treatment with certain classes of antidepressants may be
mediated by the BDNF allele of the patient.
SEROTONIN-RELATED POLYMORPHISMS AND MOUSE MODELS
Several studies have assessed the effects of various mutations in
the serotonergic system on depression and anxiety-related behav-
ior (see Supplementary Table 2 for an overview). The most com-
monly prescribed class of antidepressants (SSRIs) targets SERT
and ultimately results in increased levels of serotonin in the brain.
Therefore, it is not surprising that multiple components of the
serotonergic system are involved in mediating the antidepres-
sant response. However, a few polymorphisms in humans that
are associated with mood disorders and treatment resistance have
been described for the serotonergic system.
The best understood polymorphism in the serotonergic system
occurs in the promoter region of the gene encoding SERT. This
polymorphism is more commonly referred to as the serotonin
transporter linked polymorphic region (5-HTTLPR) (Lesch et al.,
1996). Insertion or deletion of a 44-base pair (bp)-long region
gives rise to short “S” and long “L” forms of the promoter region,
and the “S” form is associated with lower levels of transporter
expression (Lesch et al., 1996; Murphy et al., 2004). This poly-
morphism has been linked to vulnerability to depression when
accompanied by stressful life events, increased anxiety-related
measures, and resistance to antidepressant treatment (Caspi et al.,
2003; Lopez-Leon et al., 2008; Munafo et al., 2009; Taylor et al.,
2010). Several genetic mouse models have manipulated SERT
expression, and generally mice with decreased SERT expression
display more depression-like behavior, resistance to SSRIs, and
altered responses to TCAs relative to wild-type mice (Holmes
et al., 2002; Lira et al., 2003; Carola and Gross, 2012). Thus,
whether a depressed patient carries the “S” or “L” form of SERT
likely impacts whether or not they respond to treatment with
traditional antidepressants.
In addition to SERT, alterations in the 5-HT1A receptor also
may contribute to treatment resistance. A C(-1019)G polymor-
phism in the promoter region of the gene encoding the 5-HT1A
receptor is associated with depression and the response to antide-
pressant treatment (Wu and Comings, 1999; Le François et al.,
2008). Initial reports suggested that this polymorphism specifi-
cally impacted expression of the autoreceptor population present
on the serotonergic neurons of the Raphe nucleus (Lemonde
et al., 2003), but more recent imaging results suggest that mul-
tiple populations of 5-HT1A receptors are affected (Parsey et al.,
2006). 5-HT1A autoreceptors have also been linked with the
delayed effects of SSRIs. More specifically, the autoreceptors pro-
vide feedback inhibition to the serotonergic neurons that express
them, and progressive desensitization of these receptors has been
suggested to underlie the delay (Blier et al., 1998). While C(-
1019)G polymorphism has not yet been directly recreated in
rodents, Leonardo and colleagues created an inducible 5-HT1A
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autoreceptor knockdown line of mice (Richardson-Jones et al.,
2010). These mice have normal levels of 1A autoreceptors dur-
ing development but show approximately a 30% decrease in
1A autoreceptor levels upon induction in adulthood. Since this
30% decrease relative to controls is representative of the range
of receptor levels seen in humans, the authors suggest that the
1A autoreceptor knockdown mice modeled a low-expressing
population (1A-Low) while the control mice modeled a high-
expressing population (1A-High). Raphe neurons fire at higher
rates in the 1A-Low mice, and these mice also display increased
physiological reactivity to stress and decreased immobility in
the forced swim test relative to 1A-High mice. Interestingly, in
conditions where 1A-High mice did not show a response to
fluoxetine in the NSF test (even though the 5-HT1A autorecep-
tors were desensitized), 1A-Low mice showed a robust response.
Therefore, this paper suggests that that 5-HT1A autorecep-
tor desensitization alone is not sufficient to induce a response
and that 5-HT1A autoreceptor levels (and thus serotonin levels
throughout the brain) prior to treatment may control whether
or not an individual responds to treatment with traditional
antidepressants.
DEFINING A NEURAL CIRCUIT UNDERLYING TRD
While some studies have been performed, overall the mechanisms
underlying TRD remain unclear. In order to perform preclinical
studies aimed at defining these mechanisms, first it is necessary
to know where to look. One place to start is by investigating the
known neural circuitry underlying mood and the response to
traditional antidepressants.
THE DENTATE GYRUS SUBFIELD OF THE HIPPOCAMPUS
While several brain regions are known to be involved in the
circuitry underlying mood disorders and response to tradi-
tional antidepressants, we recently compared dentate gyrus tis-
sue between responders and non-responders using a microarray
approach. We decided to focus on the dentate gyrus for several
reasons: (1) Hippocampal neurogenesis, a process occurring in
the subgranular zone of the dentate gyrus, is required for the
response to most antidepressants (Santarelli et al., 2003; David
et al., 2009); (2) Local pharmacological manipulations, such
as BDNF or Activin infusion into the dentate gyrus, yield an
antidepressant-like response (Shirayama et al., 2002; Dow et al.,
2005); (3) the dentate gyrus contains a relatively homogenous
population of cell types relative to other brain areas.; and (4)
the practical reason that we have identified a specific behavior,
NSF, which requires an intact dentate gyrus and is responsive
to antidepressant treatment (Santarelli et al., 2003; David et al.,
2009; Samuels et al., 2014). We compared dentate gyrus gene
expression between responders and non-responders and found an
overall shift in genomic tone. However, we also found several spe-
cific pathways, such as TGFβ and NFκB, that may be targetable
(Samuels et al., 2014).
One potential circuit underlying TRD may center on the den-
tate gyrus (and thus the hippocampus) (Figure 1). The involve-
ment of the hippocampus in anxiety-like behavior is profound;
it is central to the circuitry of the stress response. Several clas-
sic studies demonstrated that the hippocampus is involved in the
regulation of mood by demonstrating the vulnerability of the
hippocampus to various hormones induced by stressful experi-
ences (McEwen, 1999). In the CA3 subfield of the hippocampus,
for example, 21 days of restraint stress or corticosterone treat-
ment leads to atrophy of apical dendrites (McEwen et al., 1995;
McEwen, 1999). Adrenalectomy in adult rats causes increased
death of mature granule neurons in the dentate gyrus (Sloviter
et al., 1989; Gould et al., 1990). Adult dentate gyrus neurogene-
sis is also regulated by stress (Dranovsky and Hen, 2006; Samuels
and Hen, 2011). Exposure to different forms of chronic stress,
including social subordination, immobilization, physical restraint
and footshock can suppress adult neurogenesis inmultiple species
(Gould et al., 1997, 1998; Czéh et al., 2001, 2002). In addition,
optogenetic elevation of granule cell activity in the ventral den-
tate gyrus powerfully suppresses innate anxiety (Kheirbek et al.,
2013). For all of these reasons, the hippocampus may be an entry
point to defining a neural circuit underlying TRD.
THE HIPPOCAMPUS AND MOOD CIRCUITRY
The most likely mechanism by which stress suppresses adult
neurogenesis in the hippocampus is via activation of the HPA
axis and subsequent elevation of cortisol (glucocorticoid) levels.
Several lines of evidence support this hypothesis. First, adrenalec-
tomy increases adult DG neurogenesis (Cameron and Gould,
1994). Second, both acute and chronic treatment with corticos-
terone leads to a decrease in neurogenesis (Gould et al., 1992;
Cameron and Gould, 1994; Cameron et al., 1998; Karishma and
Herbert, 2002; Murray et al., 2008). Third, glucocorticoids also
inhibit the proliferation and differentiation of neural progen-
itors and the survival of young neurons (Wong and Herbert,
2004). Hippocampal neurons express receptors for glucocorti-
coids, which suggests that glucocorticoids have direct effects
on the hippocampus (McEwen et al., 1968; Dranovsky and
Hen, 2006). Thus, the hippocampus is strongly regulated by
stress.
Interestingly, the hippocampus also provides negative feed-
back to the HPA axis. When the hippocampus is lesioned, basal
levels of glucocorticoids increase and the stress response is pro-
longed (Jankord and Herman, 2008). This regulation appears to
be via the major output of the hippocampus, namely the ven-
tral subiculum (vSUB). The vSUB directly innervates GABAergic
neurons in several nuclei including the bed nucleus of the stria
terminalis (BNST), the nucleus of the solitary tract (NST), the
dorsomedial hypothalamus (dmHYP), and the preoptic area
(POA) (Herman and Mueller, 2006; Jankord and Herman, 2008;
Surget et al., 2011). In turn, these nuclei directly innervate and
inhibit the entry point to the HPA axis, the medial parvocellu-
lar paraventricular nucleus (mpPVN) of the hypothalamus. The
mpPVN secretes corticotropin releasing hormone (CRH), which
then excites the anterior lobe of the pituitary gland, which in
turn releases adrenocorticotropic hormone (ACTH). ACTH acti-
vates the adrenal cortex, which results in release of glucocorticoids
(Herman and Mueller, 2006). Lesions to the vSUB also enhance
HPA axis responses to stress, but do not affect basal corticosterone
levels (Herman and Mueller, 2006; Jankord and Herman, 2008).
Therefore, the hippocampus is both a target and a regulator of the
stress response.
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FIGURE 1 | A potential hippocampus-based neural circuit for TRD. Several
distinct neural circuits likely underlie resistance to traditional antidepressants.
This is one potential hippocampus-based circuit. The hippocampus regulates
the HPA axis (mpPVN > Anterior Pituitary Gland > Adrenal Cortex) through
multiple brain nuclei. Medial parvocellular paraventricular nucleus (mpPVN)
neurons receive inhibitory inputs from the bed nucleus of the stria terminalis
(BNST), the dorsomedial hypothalamus (dmHYP), the preoptic area (POA), and
the nucleus of the solitary tract (NTS). In turn, these areas receive excitatory
inputs from the ventral subiculum (vSUB) and the medial prefrontal cortex
(mPFC). The ventral hippocampus innervates and regulates the ventral
subiculum (vSUB) and the medial prefrontal cortex (mPFC). Importantly, this is
a feedback loop as corticosterone produced in the adrenal cortex regulates a
large population of receptors in the dentate gyrus of the hippocampus. In
addition, the ventral hippocampus (vHIP) regulates the nucleus accumbens
(NAc) through the ventral subiculum (vSUB) and the subgenual cingulate (SGC)
through the ventral subiculum (vSUB) and the Papez circuit. Identification of
mechanisms underlying treatment resistance in this circuitry may result in
novel therapeutic avenues.
The hippocampus also regulates regions that are known to
control mood, such as the medial prefrontal cortex (mPFC),
NAc, and SGC (Brodmann area 25). The ventral hippocampus
(vHPC) shows theta synchrony with mPFC, which in turn reg-
ulates the stress response via activation of GABAergic neurons
in BNST, NST, and POA (Jankord and Herman, 2008; Adhikari
et al., 2010). Based on the timing of the theta synchrony, the sig-
nal appears to originate from the vHPC and travels to the mPFC.
This synchrony increases while mice are in an anxiogenic envi-
ronment such as an elevated plus maze or a novel arena (Adhikari
et al., 2010). The hippocampus also innervates NAc, which as
mentioned above is a region that regulates response to social
defeat and is a target for DBS in TRD patients. One of the most
prominent subcortical efferent projections of vSUB is to NAc,
and hippocampal (CA1) and vSUB neurons demonstrate syn-
chronous activity with medium spiny neurons in NAc (Goto and
O’Donnell, 2001; Witter and Amaral, 2004). The hippocampus
also regulates SGC (Brodmann area 25), a major target of DBS,
through the Papez circuit, which has been studied for more than
a century and is affected in many memory disorders (Triarhou,
2008). Taken together, these anatomical connections suggest that
the hippocampus is a central player and regulator of the circuitry
that underlies mood.
SUMMARY AND FUTURE DIRECTIONS
While the mechanisms underlying resistance to antidepressant
treatment remain unknown, a framework is developing for mod-
eling and assessing treatment resistance in animals. One approach
that may work is to use rodent models of depression (such as
UCMS, social defeat, or CORT) to isolate responders and non-
responders to antidepressant treatment. Then, the various brain
regions involved in the circuitry underlying depression can be dis-
sected and compared between responders and non-responders.
We took this approach in a recent study and found several differ-
ences in the dentate gyrus (Samuels et al., 2014). Future studies
using this type of approach should pave the road for novel ther-
apeutic avenues that will supplement or perhaps even replace
current antidepressant treatments.
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